Gene · 79679
Papers2,409
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
901 to 920 of 2,409
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Stem signatures associating SOX2 antibody helps to define diagnosis and prognosis prediction with esophageal cancer. | Ann Med | 2022 | 35382656 | PubTator, text mining | PubMed |
| Increased Expression of SETDB1 Predicts Poor Prognosis in Multiple Myeloma. | Biomed Res Int | 2022 | 35372573 | PubTator, text mining | PubMed |
| Siglec-9, a Putative Immune Checkpoint Marker for Cancer Progression Across Multiple Cancer Types. | Front Mol Biosci | 2022 | 35372497 | PubTator, text mining | PubMed |
| Microbiota-dependent activation of the myeloid calcineurin-NFAT pathway inhibits B7H3- and B7H4-dependent anti-tumor immunity in colorectal cancer. | Immunity | 2022 | 35364006 | PubTator, text mining | PubMed |
| High-throughput identification of autoantibodies that target the human exoproteome. | Cell Rep Methods | 2022 | 35360706 | PubTator, text mining | PubMed |
| Identification of a Mitochondria-Related Gene Signature to Predict the Prognosis in AML. | Front Oncol | 2022 | 35359394 | PubTator, text mining | PubMed |
| Integrative Pan-Cancer Analysis of KIF15 Reveals Its Diagnosis and Prognosis Value in Nasopharyngeal Carcinoma. | Front Oncol | 2022 | 35359374 | PubTator, text mining | PubMed |
| Cadherin-16 inhibits thyroid carcinoma cell proliferation and invasion. | Oncol Lett | 2022 | 35350592 | PubTator, text mining | PubMed |
| Multifunctional Lipid Bilayer Nanocarriers for Cancer Immunotherapy in Heterogeneous Tumor Microenvironments, Combining Immunogenic Cell Death Stimuli with Immune Modulatory Drugs. | ACS Nano | 2022 | 35348320 | PubTator, text mining | PubMed |
| Inflammatory Response-Related Long Non-Coding RNA Signature Predicts the Prognosis of Hepatocellular Carcinoma. | J Oncol | 2022 | 35342418 | PubTator, text mining | PubMed |
| Immunosuppressive tumor-associated macrophages expressing interlukin-10 conferred poor prognosis and therapeutic vulnerability in patients with muscle-invasive bladder cancer. | J Immunother Cancer | 2022 | 35338085 | PubTator, text mining | PubMed |
| Nanomedicine as a Promising Tool to Overcome Immune Escape in Breast Cancer. | Pharmaceutics | 2022 | 35335881 | PubTator, text mining | PubMed |
| The Epstein-Barr Virus Hacks Immune Checkpoints: Evidence and Consequences for Lymphoproliferative Disorders and Cancers. | Biomolecules | 2022 | 35327589 | PubTator, text mining | PubMed |
| Current Status and Future Directions of Immunotherapies in Soft Tissue Sarcomas. | Biomedicines | 2022 | 35327375 | PubTator, text mining | PubMed |
| The Prognostic Value and Immunological Role of STEAP1 in Pan-Cancer: A Result of Data-Based Analysis. | Oxid Med Cell Longev | 2022 | 35313641 | PubTator, text mining | PubMed |
| Diagnostic Value, Prognostic Value, and Immune Infiltration of LOX Family Members in Liver Cancer: Bioinformatic Analysis. | Front Oncol | 2022 | 35311155 | PubTator, text mining | PubMed |
| Comprehensive Analysis Identified Mutation-Gene Signature Impacts the Prognosis Through Immune Function in Hepatocellular Carcinoma. | Front Oncol | 2022 | 35311113 | PubTator, text mining | PubMed |
| Deoxynivalenol triggers porcine intestinal tight junction disorder through hijacking SLC5A1 and PGC1α-mediated mitochondrial function. | Food Chem Toxicol | 2022 | 35307453 | PubTator, text mining | PubMed |
| Bioinformatical analysis of the key differentially expressed genes and associations with immune cell infiltration in development of endometriosis. | BMC Genom Data | 2022 | 35303800 | PubTator, text mining | PubMed |
| Proteomic profiling based classification of CLL provides prognostication for modern therapy and identifies novel therapeutic targets. | Blood Cancer J | 2022 | 35301276 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/79679/papers?page=46